WO2006067392A3 - Composes - Google Patents

Composes Download PDF

Info

Publication number
WO2006067392A3
WO2006067392A3 PCT/GB2005/004876 GB2005004876W WO2006067392A3 WO 2006067392 A3 WO2006067392 A3 WO 2006067392A3 GB 2005004876 W GB2005004876 W GB 2005004876W WO 2006067392 A3 WO2006067392 A3 WO 2006067392A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
tuberculosis
indole derivatives
medicament
manufacture
Prior art date
Application number
PCT/GB2005/004876
Other languages
English (en)
Other versions
WO2006067392A2 (fr
Inventor
Vijaykumar Hulikal
Ranga Rao Kajipalya Rangan Rao
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Vijaykumar Hulikal
Ranga Rao Kajipalya Rangan Rao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Vijaykumar Hulikal, Ranga Rao Kajipalya Rangan Rao filed Critical Astrazeneca Ab
Priority to JP2007547617A priority Critical patent/JP2008525394A/ja
Priority to EP05818623A priority patent/EP1904487A2/fr
Publication of WO2006067392A2 publication Critical patent/WO2006067392A2/fr
Publication of WO2006067392A3 publication Critical patent/WO2006067392A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un composé de formule (I) ou d'un sel pharmaceutiquement acceptable, ou d'un ester hydrolysable in vivo de celui-ci, dans la fabrication d'un médicament destiné à traiter Mycobacterium tuberculosis (M.tb).
PCT/GB2005/004876 2004-12-23 2005-12-16 Composes WO2006067392A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2007547617A JP2008525394A (ja) 2004-12-23 2005-12-16 化合物
EP05818623A EP1904487A2 (fr) 2004-12-23 2005-12-16 Derives de l'indole pour le traitement de la tuberculose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0428173.9A GB0428173D0 (en) 2004-12-23 2004-12-23 Compounds
GB0428173.9 2004-12-23

Publications (2)

Publication Number Publication Date
WO2006067392A2 WO2006067392A2 (fr) 2006-06-29
WO2006067392A3 true WO2006067392A3 (fr) 2007-03-08

Family

ID=34113122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/004876 WO2006067392A2 (fr) 2004-12-23 2005-12-16 Composes

Country Status (5)

Country Link
EP (1) EP1904487A2 (fr)
JP (1) JP2008525394A (fr)
CN (1) CN101087781A (fr)
GB (1) GB0428173D0 (fr)
WO (1) WO2006067392A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314732B2 (en) 2000-02-17 2008-01-01 Tfk Inc. Drug and manufacturing method of same
FR2967672B1 (fr) * 2010-11-22 2012-12-28 Sanofi Aventis Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
WO2013055674A1 (fr) * 2011-10-10 2013-04-18 The University Of Toledo Méthode de traitement d'infections
BR112015004666B1 (pt) * 2012-09-07 2022-04-26 Novartis Ag Derivados de indol carboxamida, seu uso, e composição farmacêutica
CN112250627B (zh) 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
EP3519401B1 (fr) 2016-09-30 2021-09-29 Vertex Pharmaceuticals Incorporated Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
IL277491B (en) 2016-12-09 2022-08-01 Vertex Pharma Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
EP3634402A1 (fr) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
WO2019046465A2 (fr) * 2017-08-29 2019-03-07 Rutgers, The State University Of New Jersey Indoles thérapeutiques
CN111479805A (zh) 2017-08-29 2020-07-31 罗格斯新泽西州立大学 治疗性吲唑
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (fr) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
US11807644B2 (en) * 2020-05-12 2023-11-07 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02165131A (ja) * 1988-12-20 1990-06-26 Konica Corp カブリの発生が抑えられたハロゲン化銀写真感光材料
EP0791582A1 (fr) * 1995-08-04 1997-08-27 Otsuka Kagaku Kabushiki Kaisha Derives des esters de l'acide indole-2-carboxylique, et bactericides destines a l'agriculture et a l'horticulture contenant ceux-ci comme ingredients actifs
WO1999007351A2 (fr) * 1997-08-07 1999-02-18 Zeneca Limited Composes chimiques
WO1999033800A1 (fr) * 1997-12-24 1999-07-08 Aventis Pharma Deutschland Gmbh Utilisation de derives indoliques comme inhibiteurs du facteur xa
WO2000046195A1 (fr) * 1999-02-05 2000-08-10 Astrazeneca Ab Derives d'indole anti-inflammatoires
US6352958B1 (en) * 1997-02-26 2002-03-05 Fmc Corporation Cycloimido-substituted benzofused heterocyclic herbicides
US6372752B1 (en) * 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02165131A (ja) * 1988-12-20 1990-06-26 Konica Corp カブリの発生が抑えられたハロゲン化銀写真感光材料
EP0791582A1 (fr) * 1995-08-04 1997-08-27 Otsuka Kagaku Kabushiki Kaisha Derives des esters de l'acide indole-2-carboxylique, et bactericides destines a l'agriculture et a l'horticulture contenant ceux-ci comme ingredients actifs
US6352958B1 (en) * 1997-02-26 2002-03-05 Fmc Corporation Cycloimido-substituted benzofused heterocyclic herbicides
WO1999007351A2 (fr) * 1997-08-07 1999-02-18 Zeneca Limited Composes chimiques
US6441004B1 (en) * 1997-08-07 2002-08-27 Zeneca Limited Monocyte chemoattractant protein-1 inhibitor compounds
WO1999033800A1 (fr) * 1997-12-24 1999-07-08 Aventis Pharma Deutschland Gmbh Utilisation de derives indoliques comme inhibiteurs du facteur xa
WO2000046195A1 (fr) * 1999-02-05 2000-08-10 Astrazeneca Ab Derives d'indole anti-inflammatoires
US6372752B1 (en) * 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERTHOLD H ET AL: "Identification of cardiotonic sodium channel activators by potassium depolarization in isolated guinea-pig atria.", JOURNAL OF PHARMACOLOGICAL METHODS., vol. 24, no. 2, September 1990 (1990-09-01), pages 121 - 135, XP002393947, ISSN: 0160-5402 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, LEE JENG-JONG ET AL: "Catalysis of decarboxylation of 6-nitrobenzisoxazole-3-carboxylate by cationic polymer colloids", XP002393946, Database accession no. PREV199396083201 *
JOURNAL OF ORGANIC CHEMISTRY, vol. 58, no. 15, 1993, pages 4070 - 4077, ISSN: 0022-3263 *
KETTLE JASON G ET AL: "N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS., vol. 14, no. 2, 19 January 2004 (2004-01-19), pages 405 - 408, XP002393948, ISSN: 0960-894X *
PATENT ABSTRACTS OF JAPAN vol. 014, no. 422 (P - 1104) 12 September 1990 (1990-09-12) *

Also Published As

Publication number Publication date
JP2008525394A (ja) 2008-07-17
WO2006067392A2 (fr) 2006-06-29
CN101087781A (zh) 2007-12-12
EP1904487A2 (fr) 2008-04-02
GB0428173D0 (en) 2005-01-26

Similar Documents

Publication Publication Date Title
WO2006067392A3 (fr) Composes
WO2009054479A1 (fr) Compose spiro-cyclique et utilisation de ce compose a des fins medicales
WO2007087395A3 (fr) INHIBITEURS DE mTOR INSATURES
WO2008075068A3 (fr) Nouveaux composés
WO2008115516A8 (fr) Dérivés d'isoindoline 4'-o-substitués, compositions renfermant ces dérivés et procédés d'utilisation associés
WO2007003962A3 (fr) Agonistes de gpcr
WO2007003961A3 (fr) Agonistes de gpcr
WO2007117465A3 (fr) Composés d'indazole
WO2007061737A3 (fr) INHIBITEURS mTOR BICYCLIQUES CONDENSES
IL180916A0 (en) Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
WO2006098918A3 (fr) Gamma lactames substitues en tant qu'agents therapeutiques
WO2008001101A3 (fr) Combinaisons pharmaceutiques
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2008120725A1 (fr) Nouveau dérivé de pyrrolinone et composition médicale le contenant
WO2005021544A3 (fr) Inhibiteurs d'un ensemble d'imidazopyridine c n3 substitue
WO2008008660A3 (fr) Composés thérapeutiques
WO2008006795A3 (fr) Composés d'indole
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2007112913A3 (fr) Derives de benzimidazole
WO2008004100A3 (fr) Composés thérapeutiques
WO2008093838A1 (fr) Dérivé de pyridyl imidazolidine ayant un groupe sulfamoyle, et utilisation pharmaceutique de ce dérivé
MX2008002063A (es) Derivados de pirazolona para el tratamiento de tuberculosis.
MX2007003911A (es) Derivados y usos de benzoxazina y quinoxalina.
UA88766C2 (ru) Производные хинолина для лечения латентного туберкулеза

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005818623

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007547617

Country of ref document: JP

Ref document number: 200580044401.6

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05818623

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2005818623

Country of ref document: EP